Welcome to our dedicated page for LataMed AI SEC filings (Ticker: LMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LataMed AI's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LataMed AI's regulatory disclosures and financial reporting.
LataMed AI Corp. reported no revenue for the three and six months ended June 30, 2026 and continues to invest in developing an AI-enabled digital healthcare platform focused on Latin America. A February 2026 asset purchase added intangible assets valued at $7,824,000, bringing total assets to that amount, all intangible, with no cash on hand.
The company recorded a net loss of $140,221 for the six months ended June 30, 2026, compared with $53,637 a year earlier, driven mainly by higher professional fees. Current liabilities were $771,081, resulting in a working capital deficit of the same amount and cumulative accumulated deficit of $29,741,007. Management states that these conditions raise substantial doubt about the ability to continue as a going concern and notes dependence on new financing. Debt consists of $355,722 in notes payable, $34,591 in convertible notes, and $88,042 in related-party notes, all generally at 10% interest and due on demand. During 2026, 12,000,000 common shares were issued for the acquired assets, and 20,000,000 common shares were exchanged for 5,000,000 non-convertible Series C Voting Preferred Stock, resulting in 36,134,795 common shares and 5,000,000 Series C preferred shares outstanding at June 30, 2026.
LataMed AI Corp. reports that, effective August 11, 2026, its common stock resumed trading under its permanent trading symbol “LMED”. This follows the expiration of the temporary symbol “LMEDD”, which had been used in connection with the company’s previously announced five-for-one (5-for-1) forward stock split. The common stock continues to trade on the OTC Markets under the LMED symbol.
LataMed AI Corp. is implementing a 5-for-1 forward stock split that became effective at the opening of trading after its corporate action appeared on the FINRA Daily List dated July 14, 2026. Common stock now trades under temporary symbol LMEDD with a “D” suffix expected for approximately twenty business days before reverting to LMED.
The split is tied to a mandatory share exchange and a new CUSIP number 21116R404, with the prior CUSIP 21116R305 suspended upon effectiveness. Shares held in brokerage or book-entry form are expected to adjust automatically, while holders of physical certificates will receive the appropriate number of post-split shares when they submit certificates through the transfer agent.
The company continues to focus on expanding its telemedicine platform and commercializing its CardioAI, PulmoAI, and NeuroAI healthcare AI solutions, initially targeting Latin American markets.
LATAMED AI Corp. amended its Nevada charter to significantly expand its capital structure and split its stock. Authorized common stock increased from 700,000,000 shares to 3,500,000,000 shares, par value $0.0001 per share, and authorized preferred stock increased from 300,000,000 shares to 1,500,000,000 shares, par value $0.0001 per share. The change also effected a five-for-one forward split of issued and outstanding common shares, reclassifying each one share into five shares of common stock.